Similar extended VTE prophylaxis efficacy and safety between rivaroxaban and aspirin following TJA .
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2019;7(3):7 N Engl J Med. 2018 Feb 22;378(8):699-7073427 patients who had undergone either total knee or hip arthroplasty with a 5-day course of rivaroxaban 10mg postoperatively were randomized to extended thromboprophylaxis with either aspirin 81mg daily or continued rivaroxaban 10mg daily. Patients were assessed for the incidence of venous thromboembolism, major bleeding events, and clinically relevant nonmajor bleeding events over the first 90 days after surgery. Noninferiority analysis for efficacy demonstrated that extended aspirin was noninferior to extended rivaroxaban. Groups also demonstrated no significant difference in the incidence of bleeding events.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!
0 of 4 monthly FREE articles unlocked
